Abstract
Local injections of aclacinomycin A adsorbed onto activated carbon particles (ACR-CH) augmented the cytotoxic activities of regional lymph node cells for 7 days. In contrast NK-activity was only slightly augmented by injections of aclacinomycin A (ACR) solution or activated carbon suspension. The effects were found in lymphocytes from all regions tested. NK-activity could only be detected when both adherent and non-adherent cells were present. The cell number of L3T4+ cells in each type of lymph node tested increased, and subset analysis of the lymphocyte subpopulations revealed an increase in the ratio of L3T4+/Lyt2+ cells, suggesting that the ACR-CH selectively increased and stimulated L3T4+ cells. Enhanced capacity of lymph node cells to produce cytokines, tumor necrosis factor (TNF) and interleukin-1 (IL-1) upon restimulation (with LPS) in vitro in the ACR-CH treated group was found. From these results, it appears that the new dosage form of aclacinomycin A, ACR-CH, with superior therapeutic efficacy against lymph node metastases, can also enhance the immune response of regional lymph node cells. The findings reported here will be valuable in the establishment of novel chemoimmunotherapeutic protocols using ACR-CH.
References
Sep 15, 1978·Cellular Immunology·S B MizelJ J Oppenheim
Jan 1, 1979·Immunological Reviews·R B HerbermanP Puccetti
Jun 1, 1992·Anti-cancer Drugs·C SakakuraM Shirasu
Jun 24, 1991·Journal of Immunological Methods·M J BaarschM P Murtaugh
Jun 1, 1991·Anti-cancer Drugs·A HagiwaraS Muranishi
Oct 1, 1991·Laboratory Animals·M KishimaN Goto
Oct 25, 1991·Journal of Immunological Methods·D R BranchL J Guilbert
Oct 1, 1991·American Journal of Surgery·H WaneboS Mehta
Jan 1, 1990·International Journal of Immunopharmacology·J LimpensR J Scheper
Jan 1, 1989·International Archives of Allergy and Applied Immunology·H C MaguireW P Weidanz
Jan 1, 1989·Cancer Immunology, Immunotherapy : CII·A M ClaessenR J Scheper
Jan 1, 1985·Advances in Cancer Research·R J North
Oct 1, 1986·The Journal of Experimental Medicine·A DiGiacomo, R J North
Jan 1, 1988·Cancer Investigation·D Berd, M J Mastrangelo
Jan 1, 1987·Cancer Immunology, Immunotherapy : CII·K NaraT Abo
Jan 1, 1986·Cancer Immunology, Immunotherapy : CII·T NishimuraY Hashimoto
Sep 1, 1980·The Journal of Experimental Medicine·J G HowardF Y Liew
Mar 1, 1981·The Journal of Antibiotics·M IshizukaH Umezawa
Apr 1, 1982·The Journal of Experimental Medicine·R J North
Aug 1, 1984·Journal of the National Cancer Institute·R GiavazziI R Hart
Jan 1, 1982·Immunological Reviews·S B Mizel
Jan 1, 1982·Cancer Immunology, Immunotherapy : CII·T OguraY Yamamura
Jan 1, 1982·International Archives of Allergy and Applied Immunology·S Orbach-ArbouysG Mathe
Aug 1, 1963·Proceedings of the National Academy of Sciences of the United States of America·V N IYER, W SZYBALSKI
Citations
May 30, 1998·Journal of Advanced Nursing·K Seers, D Carroll
Jul 1, 1995·The International Journal of Clinical and Experimental Hypnosis·B EnqvistH Bystedt
Jul 1, 1996·The International Journal of Clinical and Experimental Hypnosis·R Kessler, J R Dane
Mar 6, 2010·Psychology & Health·Michael ShelleyIan Frazer
Feb 2, 2012·Neuropsychological Rehabilitation·Jason LandonSimone Freundlich
Dec 18, 2013·Journal of Clinical Nursing·Suzanne DenieffeMartina Gooney
Jan 31, 2008·British Journal of Health Psychology·John WeinmanMary Dyson
May 15, 2018·PloS One·Yan Ling LaiWilliam Huynh
Dec 14, 2011·The Cochrane Database of Systematic Reviews·Khadra GalaalAlberto D Lopes